When it comes to releasing the AstraZeneca vaccine with an atypical affection for sanguine coagulas, the Johnson & Johnson, based on the technology, is the blank of the suspects. What do you mean by respect?
What was observed?
In both cases, the various suspects are able to detect various cases of thrombosis in evacuated persons.
No simple thrombosis, such as phlebitis, causes very habitual affections. First of all, by its location: affecting the cerebral veins and in the minor area, the abdomen, indicated the 7th of April the European Medicines Agency (EMA) on AstraZeneca.
With the vacancy of Johnson & Johnson It also observed “thrombosis of the cerebral venous arteries”, underlining the sanitary authorities of the United States, the FDA and the CDC.
These pathologies are present in a pair with a level of sanguine plaques, because in the case of sanguine coagulations, the patient may suffer from hemorrhages.
The EMA reconnaissance for the first time on April 7th, these problems are being provoked by the vacancy of AstraZeneca.
In change, this toadavia corner was not formally established with the vacancy of Johnson & Johnson, authorized pero todavía no administrada en Europa bajo el nombre de Janssen. In United States, his employee was suspended this March in the hope of a scientific response.
What’s Debe?
These problems can be related to the “viral vector” vacancy technique. It is based on how to support another virus, which is modified to transport in the body genetic information capable of combating covid.
Both use an adenovirus, a very current virus type. El de AstraZeneca is an adenovirus of chimpanzee and the Johnson & Johnson is a human.
“All indications are that there is an adenovirus vector”, explained on Twitter Mathieu Molimard, a French specialist in pharmacology, recording that this type of problem does not exist with the Pfizer / BioNTech and Modern vehicles, which use ARN messaging technology.
For now, if these pathologies are also registered with another vaccine that contains adenovirus, the Russian Sputnik V. It is authorized in 60 countries per year in the European Union and in the United States.
What are the mechanisms?
Various elements contribute to an immunological reaction that is provoked by these vacancies against the COVID-19.
In a study published online on March 28, German and Austrian investigators set up a cell with another mechanism known.
The phenomenon “appears clinically related to heparin-induced thrombocytopenia (TIH)”, indicates the team of leading scientists from Andreas Greinacher, of the University of Greifswald.
The TIH is an abnormal, severe and habitual immune response in some patients to an anticoagulant drug, heparin.
It is a “plausible explanation”, valued by the EMA on April 7, in the process of completing new studies.
What is the risk?
This is the main question. According to EMA figures, as of April 4, 222 atypical thrombosis cases have been detected over 34 million injections performed with AstraZeneca in the 30 countries of the European Economic Area (EU, Iceland, Norway, Liechtenstein) and United Kingdom. With a balance of 18 deaths up to March 22nd.
The thrombosis is produced “during the two consecutive weeks of evacuation”, according to the EMA.
In the case of Johnson & Johnson, the authorities in the state register six cases, between these and one decade, between more than 6.8 million administered doses, and the apparent syndromes between 6 and 13 days after the injection.
But, as with all medicines, the key is to weigh the risks and the benefits.
“Global benefits of vaccination prevention COVID-19 more than the risks of secondary effects “, the EMA respects AstraZeneca.
What are the risk factors?
Currently, the majority of cases with AstraZeneca is held in “women less than 60 years”, according to the EMA. The six cases detected in the United States with Johnson & Johnson eran mujeres de entre 18 y 48 años.
Pero es demasiado temprano para sacar volggtrekkings. For now, “we have not identified any specific risk factor”, the EMA has respected AstraZeneca.
After the first round of suspensions, in mid-March, some countries will decide to use the vaccine for a fixed period of time: 30 years in the United Kingdom, 55 years in France, Belgium and Canada; 60 af Alemania y Holanda, y 65 af Suecia y Finlandia.
“Not only do we have a vacancy, we do vary. For that, I understand that you feel reserved for the AstraZeneca a las personas mayores “, verklaar una viróloga de la Universidad Goethe de Fráncfort, Sandra Ciesek, a la revista Science.
The authorities of the United Kingdom will distribute a graphic that demonstrates that the COVID-19 supone un riesgo para la salud seis veces burgemeester que la vacuna en edades comprendidas entre 20-29 años. Peru in France 60-69 years, the risk is 600 more important.
Norway and Denmark opt to suspend altogether the use of the vaccine AstraZeneca.
NUESTROS PODCAST
“Vital space”: To determine which variants are predominant in a country requires a permanent genomic vigilance. What is this process and why is it important? El Dr. Elmer Huerta does not explain the details.
Newsletter All about coronavirus
COVID-19 has been alerted to all. Subscribe to our newsletter Everything about coronavirus, where you will find the most relevant diary dates of the country and the world about the advance of the virus and the loop against its propagation.